From: Prosthetic joint infection development of an evidence-based diagnostic algorithm
Author | Year | LoE | CoR | (n = x) | Sensitivity | Specificity | Positive predictive value | Negative predictive value | LR for a positive result | LR for a negative result |
---|---|---|---|---|---|---|---|---|---|---|
Bottner et al. | 2007 | I | I | 78 | Â | Â | Â | Â | Â | Â |
 CRP (1.5 mg/dl) |  |  |  |  | 0.95 (0.86–1.0) | 0.91 (0.94–0.99) | 0.8 (0.64–0.96) | 0.98 (0.94–1.0) | 10.86 (5.3–73.07) | 0.05 (0.0–0.17) |
 ESR (32 mm/h) |  |  |  |  | 0.81 (0.64–0.98) | 0.89 (0.82–0.97) | 0.74 (0.56–0.92) | 0.93 (0.8–1.0) | 7.69 (3.47–38.2) | 0.21 (0.02–0.44) |
Savarino et al. | 2004 | I | I | 26 | Â | Â | Â | Â | Â | Â |
 ESR (50 mm/h) |  |  |  |  | 0.6 (0.3–0.9) | 0.94 (0.82–1.0) | 0.86 (0.71–1.0) | 0.79 (0.61–0.97) | 9.6 (1.64–16.1) | 0.43 (0.09–0.86) |
 CRP (2 mg/dl) |  |  |  |  | 0.38 (0.14–0.61) | 0.7 (0.42–0.98) | 0.67 (0.36–0.97) | 0.42 (0.18–0.65) | 1.25 (0.24–38.34) | 0.89 (0.39–2.07) |
Kamme et al. | 1980 | I | I | 63 | Â | Â | Â | Â | Â | Â |
 ESR(30 mm/h) |  |  |  |  | 0.89 (0.8–0.99) | 0.72 (0.54–0.9) | 0.83 (0.71–0.94) | 0.82 (0.66–0.98) | 3.2 (1.75–9.54) | 0.15 (0.01–0.37) |
Greidanus et al. | 2007 | I | I | 151 | Â | Â | Â | Â | Â | Â |
 ESR (30 mm/h) |  |  |  |  | 0.82 (0.71–0.93) | 0.88 (0.81–0.94) | 0.74 (0.62–0.86) | 0.92 (0.87–0.97) | 6.7 (3.84–15.52) | 0.2 (0.07–0.36) |
 CRP (1.0 mg/dl) |  |  |  |  | 0.93 (0.86–1.0) | 0.83 (0.76–0.9) | 0.7 (0.58–0.82) | 0.97 (0.93–1.0) | 5.5 (3.57–10.23 | 0.08 (0.01–0.18) |
Della Valle et al. | 2007 | I | I | 94 | Â | Â | Â | Â | Â | Â |
 ESR (30 mm/h) |  |  |  |  | 0.9 (0.81–0.99) | 0.66 (0.53–0.79) | 0.67 (0.55–0.8) | 0.9 (0.8–0.99) | 2.66 (1.74–4.68) | 0.15 (0.01–0.35) |
 CRP (1 mg/dl) |  |  |  |  | 0.95 (0.89–1.00) | 0.75 (0.64–0.87) | 0.75 (0.63–0.87) | 0.95 (0.89–1.0) | 3.88 (2.45–7.86) | 0.06 (0.02–0.18) |
Schinsky et al. | 2008 | I | I | 201 | Â | Â | Â | Â | Â | Â |
 ESR (30 mm/h) |  |  |  |  | 0.96 (0.91–1.0) | 0.39 (0.31–0.47) | 0.37 (0.29–0.45) | 0.97 (0.92–1.0) | 1.58 (1.33–1.91) | 0.09 (0.0–0.28) |
 CRP (1 mg/dl) |  |  |  |  | 0.95 (0.89–1.0) | 0.71 (0.94–1.0) | 0.55 (0.45–0.65) | 0.97 (0.94–1.0) | 3.29 (2.45–4.69) | 0.08 (0.0–0.18) |
Fink et al. | 2007 | I | I | 145 | Â | Â | Â | Â | Â | Â |
 CRP (1.35 mg/dl) |  |  |  |  | 0.73 (0.59–0.86) | 0.81 (0.73–0.88) | 0.59 (0.45–0.73) | 0.89 (0.82–0.95) | 3.81 (2.21–7.48) | 0.34 (0.15–0.56) |
Bottner et al. | 2007 | I | I | 78 | 0.95 | 0.87 | 0.74 | 0.98 | n.p. | n.p. |
 IL-6 (>12 pg/ml) |  |  |  |  | 0.43 | 0.94 | 0.75 | 0.85 | n.p. | n.p. |
 TNF-a (>40 nl/ml) |  |  |  |  | 0.33 | 0.98 | 0.87 | 0.8 | n.p. | n.p. |
 PCT (>0.3 ng/ml) |  |  |  |  |  |  |  |  |  |  |
Di Cesare et al. | 2005 | III | III | 58 | Â | Â | Â | Â | Â | Â |
 Il-6 (>10 pg/ml) |  |  |  | 1 | 0.95 (0.89–1.0) | 0.88 (0.73–1.0) | 1 | 21.5 (9.14–60.85) | 0 |